In India, between 2005 and 2012, 80 patients died and another 500 suffered adverse effects in clinical trials.
In England, in March 2006, a phase I clinical trial testing regarding TGN1412 resulted in an accident causing a multi-organ failure syndrome in six volunteers. The company TeGenero that had developed the drug filed for bankruptcy.
In France, in January 2016, a clinical study on a BIA 10-2474 34 molecule, active in the endocannabinoid system was performed on six people in phase I. The six testers had to be hospitalized. The first patient was pronounced dead a few days later. Four may sustain permanent damage, and remain under observation.